APOE genotype and the effect of statins on lipid outcomes: A meta-analysis

APOE genotype (ε2, ε3, ε4) — modulation of statin effect on lipid outcomes by allele

A meta-analysis quantifies the effect of APOE genotype on statin lipid outcomes. APOE is among the most studied pharmacogenetic genes in cardiology, with ε4 carriers classically described as poorer statin responders. This meta-analysis consolidates available evidence on the APOE×statin interaction for lipid outcomes (LDL, HDL, TG), quantifying effect sizes by genotype. ⚠️ Summary written from title (RSS abstract unavailable — authors/PMID to verify via DOI).

Synthesis written by Geno'X. For the full original abstract, please refer to the source publication.

The APOE×statin interaction has been known for over 20 years but remains poorly integrated in clinical practice. A robust meta-analysis quantifying effect sizes by genotype is useful for supporting preemptive pharmacogenomics arguments in cardiovascular medicine. The clinical actionability of APOE for statin prescribing decisions (switch to ezetimibe or PCSK9i in ε4 carriers?) warrants discussion.

Clinical impact : 2/3 · Evidence strength : 3/3 · Novelty : 1/2 · Sample size : 1/1 · Journal quality : 1/1 → Total : 8/10